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Improvement in indices of cellular protection after
psychological treatment for social anxiety disorder
Kristoffer N. T. Månsson1,2,3, Daniel Lindqvist4, Liu L. Yang 5,6, Cecilia Svanborg 7, Josef Isung 7, Gustav Nilsonne 8,9,
Lise Bergman-Nordgren7, Samir El Alaoui7, Erik Hedman-Lagerlöf8, Martin Kraepelien7, Jens Högström7,
Gerhard Andersson10,7, Carl-Johan Boraxbekk 11,12, Håkan Fischer2, Catharina Lavebratt 5,6,
Owen M. Wolkowitz13 and Tomas Furmark3
Abstract
Telomere attrition is a hallmark of cellular aging and shorter telomeres have been reported in mood and anxiety
disorders. Telomere shortening is counteracted by the enzyme telomerase and cellular protection is also provided by
the antioxidant enzyme glutathione peroxidase (GPx). Here, telomerase, GPx, and telomeres were investigated in
46 social anxiety disorder (SAD) patients in a within-subject design with repeated measures before and after
cognitive behavioral therapy. Treatment outcome was assessed by the Liebowitz Social Anxiety Scale (self-report),
administered three times before treatment to control for time and regression artifacts, and posttreatment.
Venipunctures were performed twice before treatment, separated by 9 weeks, and once posttreatment. Telomerase
activity and telomere length were measured in peripheral blood mononuclear cells and GPx activity in plasma. All
patients contributed with complete data. Results showed that social anxiety symptom severity was significantly
reduced from pretreatment to posttreatment (Cohen’s d= 1.46). There were no significant alterations in telomeres or
cellular protection markers before treatment onset. Telomere length and telomerase activity did not change
significantly after treatment, but an increase in telomerase over treatment was associated with reduced social anxiety.
Also, lower pretreatment telomerase activity predicted subsequent symptom improvement. GPx activity increased
significantly during treatment, and increases were significantly associated with symptom improvement. The
relationships between symptom improvement and putative protective enzymes remained significant also after
controlling for body mass index, sex, duration of SAD, smoking, concurrent psychotropic medication, and the
proportion of lymphocytes to monocytes. Thus, indices of cellular protection may be involved in the therapeutic
mechanisms of psychological treatment for anxiety.
Introduction
Psychiatric disorders have been linked to increased risks
of somatic illnesses and even premature death1, although
the underlying mechanisms are not clear. Recent studies
raise the possibility that accelerated cellular aging and
deficiencies in cellular protection contribute to this
association2,3. An often-used indicator of accelerated
cellular aging is telomere length measured in blood leu-
kocytes. Telomeres protect the chromosomes from
damage and shorten with age4. They are restored by the
major telomere-lengthening enzyme telomerase5,6. Oxi-
dative stress also contributes to accelerated cellular aging
and cellular apoptosis7–9, and this process can be coun-
teracted by antioxidant enzymes, such as glutathione
peroxidase (GPx)10. A large study including >1200 parti-
cipants found that anxiety-disordered patients, relative to
healthy controls, exhibit shorter mean leukocyte telomere
length11. This is in alignment also with other studies on
disorders of the anxiety and affective spectrum12,13,
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including depression and posttraumatic stress disorder—
for a review see Darrow et al.14. Thus, it is likely that
accelerated cellular aging is involved in the pathophy-
siology of anxiety. Preclinical data suggest that these
effects could be modulated by a compensatory activation
of telomerase or GPx10,15. Moreover, telomerase activa-
tion may represent a biological mechanism mediating
treatment efficacy of various psychotropics, including
antidepressants15, lithium16, and antipsychotics17. A
small-scale study showed that antidepressant response to
a selective serotonin reuptake inhibitor (SSRI) was asso-
ciated with lower pretreatment telomerase and a greater
increase in telomerase activity over the course of treat-
ment18. Markers of oxidative stress have also been related
to treatment outcome19, e.g., increased oxidative stress is
associated with poorer response to antidepressants20.
There are also studies in healthy individuals proposing
that meditation training may be associated with increased
mononuclear cell telomerase activity21–23, and
telomerase-stress reduction relationships have also been
reported in obese women after mindfulness training24.
Moreover, human and animal studies suggest that phy-
sical exercise increases telomerase activity25. It is also
possible that beneficial effects of psychosocial interven-
tions are linked to reduced oxidative stress. For instance,
there are studies showing reductions in oxidized low-
density lipoprotein after cognitive behavioral therapy
(CBT) for sleep disturbance26 and major depression27.
There are early reports suggesting a decrease in GPx after
SSRI treatment for major depression28 and social anxi-
ety29, while more recent studies have not found SSRI-
associated GPx changes after short-30,31 or long-term32
treatment of depression. Thus, previous studies on this
topic are still scarce, treatments and study populations
vary, and findings have been mixed.
In sum, there is a growing literature pointing to the
importance of telomere biology in psychiatric disorders
and that telomere-related cellular protection may be tar-
geted by psychosocial and behavioral interventions. To
our knowledge, no previous study has investigated chan-
ges in telomerase and GPx activity after psychological
treatment for a psychiatric disorder.
Anxiety disorders, including social anxiety disorder
(SAD), are highly prevalent and debilitating psychiatric
conditions33. In the US, the estimated lifetime prevalence
is 28.8% for anxiety disorders and 12.1% for SAD34.
Among currently available treatment options, CBT and
SSRIs are efficacious35. However, despite robust
effects35,36, a large proportion, ~40–50% of patients with
SAD, has been reported to be either treatment resistant or
not responding sufficiently to current treatments37.
Identifying biomarkers involved in the anxiolytic response
could potentially improve current clinical practice by
providing targets for novel interventions and increase
treatment precision. CBT delivered via the internet is a
promising strategy to treat patients with SAD, and there is
evidence suggesting that internet-delivered CBT is as
effective as conventional CBT for this condition38.
Internet-delivered interventions provide an excellent
research context for clinical trials, e.g., with respect to
facilitated monitoring of treatment compliance and pro-
gress39. We have previously evaluated internet-delivered
CBT for SAD by use of functional and structural magnetic
resonance imaging (MRI)40,41, noting a CBT-related
reduction of amygdala activity as previously demon-
strated for traditional CBT and SSRI pharmacotherapy42.
Thus, robust effects can be expected from internet-
delivered CBT for SAD, and this treatment can be used as
a means to further our understanding of the biological
mechanisms of action in psychological treatments.
The purpose of the present study was to investigate the
relationship between telomerase and GPx enzyme activ-
ities, relative telomere length, and social anxiety symptom
reduction after psychological treatment for SAD. We
hypothesized that the response to CBT would be asso-
ciated with improved cellular protection, as indexed by
increased telomerase and GPx enzyme activities.
Materials and methods
The study was registered at ClinicalTrials.gov (id:
NCT01312571), and approval was obtained from the
regional ethics committee at Umeå University, Sweden
(dnr: 2015-310-31M). All participants gave written
informed consent prior to participation.
Participants
Media ads targeting individuals experiencing social
anxiety were used for recruitment, and individuals
responded by answering online questionnaires on demo-
graphics and social anxiety, including the Liebowitz Social
Anxiety Scale Self-Report (LSAS-SR)43. All participants
were at least 18 years of age, had no neurological disorder,
no concurrent psychological treatment and if treated with
a psychotropic medication, they agreed to maintain a
stable dose at least 3 months before enrollment and
during treatment in the current study. All participants
also met MRI safety criteria, e.g., not being pregnant and
having no ferromagnetic object in the body.
A total of 51 patients with SAD were recruited, but after
dropout (n= 2) and incidental findings after initial MRI
(n= 3), 46 participants entered treatment. All of them
remained for the final assessments. Before treatment and
baseline assessments, the patients were interviewed via
telephone using the full Mini-International Neu-
ropsychiatric Interview (M.I.N.I.) version 7.0 and the
social phobia section of the Structured Clinical Interview
for DSM-IV—Axis I Disorders (SCID-I). The patients had
to meet the diagnostic criteria for SAD as their principal
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diagnosis. Patients were excluded if they had a severe
ongoing depression (as indexed by scoring > 34 on the
self-rated Montgomery Åsberg Depression Rating Scale,
MADRS-S)44, current bipolar or psychotic disorders,
current alcohol or substance use disorders, or antisocial
personality disorder. Other acute illness was not an
exclusion criterion.
Four (9%, n= 4/46) patients were on concurrent psy-
chotropic medication, i.e., stable dosage of SSRIs that did
not change throughout the study period. Two (4%, n= 2/
46) patients had previously used beta blockers in social
situations but agreed not to use them during the study
period. Seventeen (37%, n= 17/46) had previous experi-
ence with some form of psychological treatment but no
one had an ongoing therapy. Also, the patients did not
change their level of physical exercise during the study, as
assessed with a single open-ended question. At the time of
recruitment, one patient was on short-term sick leave due
to non-psychiatric reasons (and was later not identified as
an outlier on any biomarker), all the others were currently
employed or students. See Table 1 for a detailed summary
of descriptive characteristics. Power calculation based on
the main finding in Wolkowitz et al.18 (telomerase activity
change correlating with change in depressive symptoms),
suggest that the achieved power in this study was above
99%.
General procedure and design
This study used a within-subject design including
screening, and two baseline assessments before treatment
initiation (pretreatment), and one assessment at post-
treatment. Multiple baseline assessments were included to
control for standard confounds related to time and
measurements, like regression to the mean, repeated
testing, and spontaneous remission. Two baseline
assessments were separated by 9 weeks, which equals the
number of weeks of the current intervention. All 46
patients contributed with complete clinical and biomarker
data, and there were no missing data on the primary
clinical outcome measure.
Clinical assessment
The LSAS-SR is a 24-item self-report questionnaire
used internationally to assess treatment-related changes
in social anxiety symptoms45. LSAS-SR was the primary
outcome and all patients completed assessments at
screening, first and second baseline, and posttreatment.
Internet-delivered CBT
Internet-delivered CBT for SAD has been described
extensively elsewhere46,47. Relative to conventional CBT,
patients should go through the same behavioral changes,
i.e., only the administration format differs. Briefly,
the internet-delivered CBT was a guided self-help
intervention lasting 9 weeks47. Each week, the patients
were provided with a module containing text and home-
work assignments based on CBT. The content was
Table 1 Demographics, clinical status, concurrent
medications, and comorbid conditions in the sample.
Variable Social anxiety disorder
patients, n= 46
Female gender, n (%) 29 (63.0)
Age (mean ± s.d.) 30.7 ± 8.3
SAD, duration in years (mean ± s.d.) 17.0 ± 9.9
BMI (mean ± s.d.) 24.8 ± 4.4
Smoking regularly the past 3 months,
n (%)
4 (9.0)
Marital status, n (%)
Married/cohabiting with children 16 (34.8)
Married/cohabiting without children 10 (21.7)
Noncohabiting partner 4 (8.7)
Single with children 4 (8.7)
Single without children 9 (19.6)
Other 3 (6.5)
Education, n (%)
Completed primary school 3 (6.5)
Completed secondary school 7 (15.2)
Completed vocational education 2 (4.3)
Ongoing university education 16 (34.8)
Completed university education 16 (39.1)
Concurrent medications, n (%)
No medication 18 (39.1)
SSRIs 4 (8.7)
Hormonal contraceptives 16 (34.8)
Antihistamines 1 (2.2)
Hormone medications 1 (2.2)
Thyroid hormone substitution 2 (4.4)
Concurrent psychiatric comorbidity (M.I.N.I.), n (%)
No concurrent psychiatric
comorbidity
12 (26.1)
Major depressive disorder 3 (6.5)
Panic disorder 3 (6.5)
Agoraphobia 5 (10.9)
Generalized anxiety disorder 3 (6.5)
Binge eating disorder 1 (2.2)
Obsessive compulsive disorder 2 (4.3)
BMI body mass index, M.I.N.I. Mini-International Neuropsychiatric Interview, SAD
social anxiety disorder, SSRIs selective serotonin reuptake inhibitors
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standardized, i.e., all were provided with the same mate-
rial, and identical to our previous randomized controlled
trials (RCTs), e.g., refs. 47,48. Exposure-based exercises, a
main treatment component, were introduced midway, i.e.,
in the fifth module of the treatment. Patients were in
weekly contact with a clinical psychologist providing
written feedback and guidance via a secured platform via
the Internet. The clinical psychologist provided feedback
on the homework assignments, and the patients under-
took a weekly test with questions related to CBT and the
content of the modules. To control for adherence, the
patients had to give 100% correct responses on the
multiple-choice questionnaire (with the possibility of
redoing the test multiple times). After completion of the
homework assignments and the multiple-choice quiz, the
next module was made available to the patient.
Clinical psychologists
Seven clinical psychologists were therapists in the cur-
rent study. Five (n= 71.4%) were licensed clinical psy-
chologists and two (n= 28.6%) were clinical psychology
students in their final year and received clinical super-
vision. At posttreatment, the therapists gave subjective
reports on each patient’s compliance to the exposure
exercises, and the ratings were “no/minor”, “satisfactory”,
or “to a large extent”.
Assays
Experienced research nurses collected all blood samples
in the morning (from 7:00 a.m. to 11:30 a.m.) after
patients had been fasting since 10:00 p.m. the night
before. To ensure compliance, all the patients received a
mobile phone text message the day before to remind
about fasting instructions. The patients were resting for
15min before the blood was obtained.
Whole blood was obtained in 8 ml BD Vacutainer®
CPT™ Mononuclear Cell Preparation Tube—Sodium
Citrate (Becton Dickinson). Plasma and mononuclear
cells, being lymphocytes and monocytes, were separated
within 15 min to 2 h of sampling according to manu-
facturer’s protocol. Briefly, whole blood was centrifuged
for 20 min at 1500 g, whereafter plasma and the mono-
nuclear cell layer were separated and centrifuged again
for 15 min at 300 g with phosphate-buffered saline added
to the cells for washing. The plasma was immediately
frozen at –80 °C. Approximately, half of the pelleted cells
were lysed by incubation with 120 µl CHAPS (Merck
Millipore, including 0.15 units/µl RiboLock [Life-
Technologies, Thermo Fisher Scientific]) on wet ice for
30 min and three short vortexes, thereafter the lysate was
stored at –80 °C.
Approximately, half of the pelleted cells were stored at
–80 °C until DNA extraction. Genomic DNA was extracted
using DNeasy® Blood & Tissue Kit (Qiagene), with a
modified protocol to reduce DNA shearing. Briefly, cell
lysis was done at 37 °C for 3 h, vortex was avoided, and
centrifugations were performed at 6000 g49. DNA con-
centration was quantified with NanoDrop ND-1000
Spectrophotometer (Nano-Drop Technologies Inc., Wil-
mington, DE, USA).
Differential leukocyte counts were determined in whole
blood collected in ethylenediaminetetraacetic acid
(EDTA) tubes by the University Hospital of Umeå.
Telomerase activity assay
Telomerase activity was assayed by modified real-time
telomeric repeat amplification protocol50. Samples, con-
trols, and standard curve dilutions were run in triplicate,
and standard curve and controls were present on all
plates. All samples from each patient were run on the
same plate. Efficiency was 95–101%. The mean of the
correlation coefficients of the standard curves were all
above 0.98. The coefficients of variation (CV) of intra-
assay Ct values for the standard dilutions of the four
plates was 1.0% and inter-assay was 0.47%. The detection
success rate was 100%, and all samples were run in the
same batch. See also Supplementary Material.
GPx activity assay
GPx activity was determined using BioVision Glu-
tathione Peroxidase Activity Colorimetric Assay Kit
(Catalog#K726-100) according to the protocol, where the
GPx activity was calculated using an NADPH standard
curve. The correlation coefficients of the standard curves
were all above 0.99. The inter-plate CV of GPx activity
was 6.3% and the within-plate CV was 4.4% calculated
from positive control run in nine 96-well plates. The
assay success rate was 100% (n= 46 at each timepoint),
and all samples were run in the same batch. See also
Supplementary Material.
Relative telomere length assay
Relative telomere length was determined using real-
time quantitative PCR according to Cawthon et al.’s
protocol51, where the relative telomere to single copy
gene (T/S) ratios was determined using a standard curve.
In brief, each DNA sample (10 ng) was assessed for the
telomere and the single-copy gene (hemoglobin-b, HBB)
in triplicate within the same 384-well plate, amplified by
using Platinum® SYBR® Green and 0.5 µM of each pri-
mer in 10 µl total reaction volume. The correlation
coefficients of the standard curves were above 0.99 for
each primer set and 384 plate. The inter-plate CV of T/S
ratio was 6.3% calculated from a patient sample run in
four 384-well plates. The detection success rate was
100%. Samples from all three timepoints per individual
were assayed in the same 384-well plate. See also Sup-
plementary Material.
Månsson et al. Translational Psychiatry           (2019) 9:340 Page 4 of 10
Possible confounders
There is evidence that smoking, sex, and body mass
index (BMI) are linked to leukocyte telomere length, i.e.,
smokers52, males53, and high BMI54 are associated with
shorter telomeres. Changes in telomerase activity are
associated with antidepressant response18. Also, in a large
study duration of depressive disorder was inversely asso-
ciated with telomere length55. In the current study, we
were interested in the psychological treatment response in
relation to biomarkers, and thus, smoking, BMI, con-
current SSRIs, and duration of illness were considered
possible confounders. For calculations of pre–post change
in telomerase and telomere length showing statistical
significance, change in the proportion of lymphocytes to
monocytes was added as a nuisance variable56.
Statistics
Demographic, clinical, and biomarker statistics were
evaluated using the STATA Statistical Software, v. 15.0
(STATA Corporation, College Station, TX, USA).
Generalized Estimating Equations (GEE) with
exchangeable correlation structure were used to evalu-
ate panel data on treatment effects across time. Linear
regression models were used to assess associations
between biomarkers and clinical outcome. The linear
regression models including biomarkers and symptom
scores were checked for outliers using measures of
influence (Cook’s D)57, discrepancy (studentized resi-
duals), and Hosmer–Lemeshow leverage. Individual
values with both high influence (Cook’s D > 4/46= 0.09)
and either high residuals (±3) or leverage (>2/46= 0.04)
were determined to be outliers. One patient’s baseline
GPx, and two patients’ baseline telomerase were out-
liers. Three patients’ telomerase change, two patients’
GPx change, and two patients’ change in telomere
length were determined to be outliers and excluded
from further linear regression. To account for normality
violations in biomarkers, nonparametric bootstrapping
(×1000) was used to estimate standard errors (Boot-
strapped Standard Errors) in the GEE’s and linear
regression models.
Within-group effect sizes (Cohen’s d) were based on
observed values and calculated by dividing the mean dif-
ference with respective standard deviations and correction
for the correlation between timepoints. Pre–post change
on LSAS-SR was determined by calculating each patient’s
change score from pretreatment (mean of the screening,
the first and second baseline assessment) to posttreatment
[posttreatment – (mean baseline)]. Similarly, the change
scores are reported for biomarkers. BMI, sex, duration of
SAD, smoking, and concurrent SSRI-treatment were
added as covariates in multiple regressions, including the
respective biomarker.
Results
Main effect of treatment on social anxiety symptoms
Self-reported social anxiety
As shown in Fig. 1, LSAS-SR scores from screening
(LSAS-SR mean= 77.98, s.e.= 3.00, 95% confidence
interval (CI) 72.09, 83.86) did not change significantly to
the first (Z= 0.78, p= 0.438) or second baseline (Z=
1.81, p= 0.071). As expected, LSAS-SR scores decreased
markedly (B= –33.46, s.e.= 2.55, Z= 13.13, p < 0.001) to
posttreatment (LSAS-SR mean= 44.52, s.e.= 3.00, 95%
CI 38.64, 50.41). The within-group Cohen’s d effect size
for improvement (difference between the mean of
screening, first and second baseline, and posttreatment)
was large (d= 1.46; 95% CI 1.05, 1.87).
Treatment compliance
The mean (±s.d.) number of completed treatment
modules was 7.8 (±1.8), and 78.3% (n= 36/46) of the
patients completed at least seven out of nine modules. Six
patients did not complete the fifth module in which the
exposure interventions were initiated; thus, 40 patients
undertook exposure interventions. The clinical psychol-
ogists estimated that 35.0% (n= 14/40) completed “some”
exposure exercises, while 47.5% (n= 19/40) performed
exposure exercises “to a large extent”.
Across all patients, there was an association between
compliance to exposure exercises and reduction of LSAS-
SR symptoms (pretreatment vs posttreatment; Adj-R2=
0.08, β= –0.31, B= –6.19, BSE= 2.47, Z= 2.51, p=
Fig. 1 Changes in social anxiety symptom severity as assessed
with the Liebowitz Social Anxiety Scale, self-rated version (LSAS-
SR), before and after the treatment (screening, first and second
baseline, and at post-treatment). LSAS-SR scores from screening
did not change significantly to the first (Z= 0.78, p= 0.438) or second
baseline (Z= 1.81, p= 0.071). As expected, LSAS-SR scores decreased
markedly (B= –33.46, Z= 13.13, p < .001) from pretreatment to
posttreatment (LSAS-SR mean= 44.52, s.e.= 3.00, 95% CI 38.64, 50.41).
Error bars represent the standard error.
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0.012). LSAS-SR at baseline was not associated with
compliance to exposure (β= –0.05, p= 0.729).
Pretreatment telomerase, GPx, and relative telomere length
as predictors of treatment response
Pretreatment telomerase activity was significantly
associated with pre–post changes in LSAS-SR (Adj-R2=
0.10, β= 0.35, B= 27.34, BSE= 11.35, Z= 2.41, p=
0.016), with lower levels of telomerase activity predicting
greater improvement in social anxiety. This association
remained after adding the proportion of lymphocytes to
monocytes (p= 0.024), BMI (p= 0.021), sex (p= 0.031),
years with SAD (p= 0.009), smoking (p= 0.018), and
concurrent SSRIs (p= 0.013) as nuisance variables. Nei-
ther pretreatment GPx activity (β= 0.19, Z= 1.53, p=
0.127) nor pretreatment telomere length (β= 0.02, Z=
0.14, p= 0.890) were significantly associated with
pre–post change in LSAS-SR symptoms. Furthermore, as
implemented in regression models with age as a covariate
of no interest, telomerase (p= 0.906), GPx (p= 0.900),
and telomere length (p= 0.870) at baseline, were not
associated with length of illness, i.e., number of years
with SAD.
Changes in telomerase and GPx activities, and telomere
length over the course of treatment
Telomerase activity was stable from first to second
baseline (B= 0.05, BSE= 0.05, Z= 1.16, p= 0.246), and
to posttreatment (B= 0.03, BSE= 0.07, Z= 0.48, p=
0.633). GPx activity was stable across the two baselines
(B= –3.45, BSE= 2.77, Z= 1.25, p= 0.213), but then
increased significantly to posttreatment (B= 9.60, BSE=
3.34, Z= 2.87, p= 0.004; see Fig. 2). After adding cov-
ariates (i.e., BMI, sex, years with disorder, smoking, and
concurrent SSRIs), the pre-to-post increase in GPx
remained significant (p < 0.006). Relative leukocyte telo-
mere length did not change from the first to second
baseline B= 0.01, BSE= 0.03, Z= 0.31, p= 0.753; or to
posttreatment, B= –0.01, BSE= 0.03, Z= 0.32, p= 0.746.
Associations between telomerase, GPx, relative telomere
length, and treatment response
Telomerase activity and treatment response Pre–post
change in telomerase activity was negatively associated
with pre–post change in LSAS-SR, indicating that patients
with increases in telomerase activity over the course of
treatment exhibited greater reduction of social anxiety
symptoms (Adj-R2= 0.09, β= –0.33, B= –25.21, BSE=
7.82, Z= 3.22, p= 0.001); Fig. 3a. Change in telomerase
activity remained significantly associated with pre–post
change in LSAS-SR also after adding baseline LSAS-SR
severity to the regression model (Adj-R2= 0.16, Z= 2.97,
p= 0.003).
GPx activity and treatment response Pre–post change
in GPx activity was negatively associated with pre–post
change in LSAS-SR, indicating that patients with
increased GPx activity showed greater reduction of social
anxiety (Adj-R2= 0.05, β= –0.28, B= –0.26, BSE= 0.11,
Z= 2.34, p= 0.024; Fig. 3b). Change in GPx activity
remained significantly associated with pre–post change in
LSAS-SR also after adding baseline LSAS-SR severity to
the regression model (Adj-R2= 0.08, Z= 2.19, p= 0.029).
Relative telomere length and treatment response Pre–post
change in relative telomere length was not significantly
associated with pre–post change in LSAS-SR (Adj-R2 < 0.01,
β= 0.14, B= 26.22, BSE= 26.11, Z= 1.00, p= 0.315).
Concurrent changes in telomerase, GPx enzyme
activities and relative telomere length Pre–post
changes in telomerase and GpX activity were not
significantly associated (β= 0.08, p= 0.565). Similarly,
telomerase (β= –0.05, p= 0.781) or GpX (β= 0.04, p=
0.844) were not significantly associated with telomere
length alterations from pretreatment to posttreatment.
Because both telomerase and GPx changes were asso-
ciated with LSAS-SR symptom change, both were
included in the same multiple regression model, which
also included telomere length changes. Alterations in
telomerase and GPx activities were still independently and
significantly associated with pre–post change in LSAS-SR
(Adj-R2= 0.26; telomerase: β= –0.32, B= –22.47, BSE=
6.64, Z= 3.38, p= 0.002; GPx: β= –0.34, B= –0.30,
BSE= 0.11, Z= 2.78, p= 0.009). Importantly, after add-
ing the covariates, i.e., BMI (p ≤ .010), sex (p ≤ .019), years
with SAD (p ≤ .012), smoking (p ≤ .004), concurrent SSRIs
(p ≤ .017), and pre–post change in proportion of lympho-
cytes to monocytes (p ≤ 0.020), the significant
Fig. 2 Glutathione peroxidase activity (GPx) was stable across the
two baselines (Z= 1.25, p= 0.213), but increased significantly
from pretreatment to posttreatment (Z= 2.87, p= 0.004). Error
bars represent the standard error.
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relationships remained between changes in LSAS-SR
symptoms and telomerase and GPx activity, respectively.
Discussion
In this longitudinal study, indices of cellular aging and
oxidative stress protection were assessed twice before, and
immediately after a psychological treatment (CBT) for a
common psychiatric disorder (SAD). A large within-
group treatment effect (Cohen’s d= 1.46) was observed
on the primary social anxiety measure, indicating sub-
stantial symptom improvement that exceeded effects
reported in our previous RCTs on internet-delivered CBT
for SAD, e.g., refs. 47,48,58. We found that putatively
enhanced cellular protection, as indexed by increases in
activity of the telomere-preserving enzyme telomerase
and antioxidant enzyme GPx, paralleled social anxiety
reduction. Also, pretreatment telomerase activity was
predictive of symptom improvement. Although enzyme
activities did not increase in all patients, those who
showed the greatest clinical improvement were more
likely to show increases in telomerase or GPx activity over
the course of treatment. Interestingly, anxiety-related
changes in GPx and telomerase activity were statistically
unrelated, suggesting at least partially independent cel-
lular mechanisms underlying the beneficial effects of
treatment. GPx is primarily involved in redox homeostasis
as well as several other important functions59, whereas,
telomerase is involved in telomere maintenance and a
wide variety of extratelomeric functions, including sus-
pected neuroprotective and antidepressant-like effects.
The intracellular effects of GPx involve enzymatic
reduction of hydrogen peroxide to water, thereby limiting
its harmful effects60. Reactive oxygen species including
hydrogen peroxide are also involved in other cellular
processes, such as mitochondrial function and growth
factor-mediated cell signaling, thus GPx may also affect
such aspects of cellular function60.
Telomere maintenance, telomerase, and oxidative stress
have complicated intracellular relationships. Telomeres
are particularly sensitive to shortening under conditions
of oxidative stress61. Telomerase re-extends telomeres,
but under conditions of oxidative stress, it shuttles from
the nucleus to the mitochondria62–64, where it protects
mitochondria biogenesis and decreases oxidative stress,
partly by potentiating cellular antioxidant defense sys-
tems, such as by increasing the ratio of reduced (GSH) to
oxidized (GSSG) glutathione65 that is catalyzed by GPx
and glutathione reductase activities. Thus, telomerase and
GPx are expected to have cellular protective effects, either
at the locus of the nucleus or the mitochondria. Apart
from affecting redox homeostasis, GPx is also involved in
several other pathways59, making it difficult to ascribe
particular functions to its role in the present findings. Due
to limitations in our ability to pinpoint the subcellular
localization of these enzymes in different clinical condi-
tions, it would be only speculative to posit specific intra-
cellular mechanisms related to the effects we report.
Increases in both telomerase and GPx activities could
reflect a more favorable cellular milieu and it is possible
that these functions are linked to symptom improvement
following CBT. This is, to the best of our knowledge, the
first study to demonstrate evidence of increased cellular
protection indices in psychiatric patients after a psycho-
social intervention.
The current findings are in line with Wolkowitz et al.18
showing that both lower baseline telomerase activity, and
greater increase in telomerase activity over 8 weeks of
SSRI treatment were associated with superior anti-
depressant response in patients with major depression. It
Fig. 3 Telomerase and glutathione peroxiades changes
associated with treatment response. a Negative association
between change in telomerase activity (pre–post) and corresponding
change in the Liebowitz Social Anxiety Scale, self-rated version (LSAS-
SR; β= –0.33, Z= 3.22, p= 0.001), indicating greater increases in
telomerase activity in patients with more reduced social anxiety after
treatment. The telomerase activity is given as (units/µl) in 0.588 µg of
total protein ([3.68 × 8] / 50). b Negative association between change
in GPx activity (pre–post) and corresponding change in the LSAS-SR
(β= –0.28, Z= 2.34, p= 0.024), indicating greater increases in GPx
activity in patients with more reduced social anxiety after treatment.
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has been speculated that improved telomerase activity is a
possible mechanism of action by psychotropic medica-
tions17. Here, we found that a psychological treatment
targeting a common anxiety disorder was associated with
increases in telomerase activity, suggesting that also
nonpharmacological interventions for psychiatric condi-
tions may influence indices of cellular aging. It is possible
that the relationship between increased telomerase
activity and successful treatment response cuts across
different treatment modalities and diagnostic groups,
although it is still unknown whether this is a causal
mechanism. With regards to behavioral change, physical
exercise can affect cellular aging and telomerase activity in
the healthy individuals without a psychiatric disorder (for
a review see Deng et al.)25. The patients in the current
study did not change their level of physical exercise
throughout the study period, making this confound
unlikely. Our results partly support the hypothesis that
accelerated cellular aging in individuals with psychiatric
conditions could be a reversible process66, and that some
of these effects, to the extent they exist, may be mediated
via mechanisms involving telomerase and/or an anti-
oxidant enzyme systems. The short-term increases in
telomerase and GPx activations were not significantly
related to telomere length. Telomeres are dynamic and
changes in leukocyte telomere length can be detected
after a few months67. The current CBT was in total
9 weeks, thus, this time frame is too narrow to determine
treatment-related telomere length alterations. Changes in
relative telomere length in association with cellular pro-
tection and reductions in social anxiety, needs to be
investigated with long-term follow-ups.
Treatment-associated increases in the antioxidative
stress marker GPx activity were related to reduced social
anxiety. There is previous evidence demonstrating CBT-
associated oxidative stress reductions in relation to
improved mental health26,27. Thus, it is possible that the
antioxidant GPx is linked to reduced anxiety and oxida-
tive stress. In the present study, we did not, however,
measure oxidative stress substrate markers, such as F2-
isoprostanes, 8-OHdG, or malondialdehyde. There are
some suggestions that GPx activity is directly, rather than
inversely, correlated with oxidation by-products, signify-
ing a homeostatic response to elevated oxidative stress68.
In the absence of other measures, it is not known if the
observed increases in GPx activity with treatment are
correlated with increased or decreased oxygen/nitrogen
free radicals. Thus, we were not able to determine net
changes in oxidative status20,69. There have been mixed
findings regarding therapeutic responses and GPx activity
alterations, with reports of no changes, increases and
reductions20,29,31. We assayed GPx activity in plasma,
whereas some other studies testing the relationship
between GPx and antidepressant response assessed GPx
activity in hemolyzed erythrocytes28,29. Although the sig-
nificance of differences between these two compartments
are not fully understood, they are genetically and immu-
nologically distinct and show different physical and
kinetic properties70. Thus, our GPx results cannot
uncritically be compared with the results of some pre-
vious studies.
This study included multiple and complete biological
assessments of all treated patients and we had no patients
dropping out from CBT. However, among the limitations
it should be noted that our study was not an RCT, thereby
lacking active treatment or psychological placebo control
groups. This is partly because the treatment program has
been evaluated previously in numerous RCTs47,48 and we
here sought to maximize the number of subjects receiving
CBT in order to reveal treatment effects on cellular
markers with sufficient statistical power. Nevertheless, we
included multiple baseline assessments to control for
standard confounds related to time and repeated testing,
noting no changes between the two baselines, marked
symptom improvement after treatment onset and a sig-
nificant association between compliance to exposure
exercises and anxiety relief. A minority of the patients had
concurrent SSRI medication, but results remained sig-
nificant after adding this as a nuisance variable. Thus, it is
reasonable to assume that improved symptomatology is
explained mainly by the psychological intervention alone.
Considering the stable pharmacotherapy and low number
of concurrent mental and somatic illnesses, other phar-
macological explanations to the current effects on telo-
merase activity and GPx are also unlikely. Telomerase
activity was measured in peripheral blood mononuclear
cells, therefore, possible changes in telomerase, but not
GPx, could be confounded by changes in the cellular
subtype composition in the blood samples obtained.
However, the ratio of these cell types was added as nui-
sance variable, and the results did not alter accordingly.
Apart from further validating internet-delivered CBT as
an effective psychological treatment for SAD, our findings
suggest improvement in indices of cellular health in tan-
dem with mental health. The current findings are novel
and need to be replicated, but provide initial evidence for
the notion that biological processes related to cellular
protection are involved in the response to a psychosocial
intervention for anxiety and are also potentially useful for
treatment prediction. Identifying biological correlates of
successful treatments, at the cellular level, could advance
our understanding of the mechanisms underlying remis-
sion, and pave the way for the development of novel
treatment options.
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